- ICH GCP
- Register voor klinische proeven in de VS.
- Klinische proef NCT07489651
RE104 Veiligheids- en Werkzaamheidsstudie bij Gegeneraliseerde Angststoornis
Een gerandomiseerd, dubbelblind, placebo-gecontroleerd onderzoek naar de veiligheid en werkzaamheid van RE104 voor injectie bij de behandeling van gegeneraliseerde angststoornis
The purpose of this study is to determine if treatment with a single and/or repeat dose of RE104 for Injection reduces anxiety symptoms in participants with Generalized Anxiety Disorder (GAD) as compared to placebo.
Studie Overzicht
Toestand
Conditie
Interventie / Behandeling
Studietype
Inschrijving (Geschat)
Fase
- Fase 2
Contacten en locaties
Studiecontact
- Naam: Mark Pollack Chief Medical Officer, M.D.
- Telefoonnummer: 1-888-880-REUN
- E-mail: info@reunionneuro.com
Studie Locaties
-
-
Alabama
-
Birmingham, Alabama, Verenigde Staten, 35209
- Werving
- University of Alabama (UAB) Clinical Research Unit (CRU)
-
Contact:
- Seher Premani
- Telefoonnummer: spremani@uab.edu
- E-mail: spremani@uab.edu
-
-
Arizona
-
Gilbert, Arizona, Verenigde Staten, 85234
- Werving
- Lighthouse Psychiatry
-
Contact:
- Matt Longson
- Telefoonnummer: 435-268-5800
- E-mail: Contact@neosciclinicalresearch.com
-
-
Arkansas
-
Little Rock, Arkansas, Verenigde Staten, 72211
- Werving
- Preferred Research Partners, Inc.
-
Contact:
- Stacy Tierney
- Telefoonnummer: 111 501-553-9987
- E-mail: stierney@preferredresearchpartners.com
-
-
California
-
Garden Grove, California, Verenigde Staten, 92845
- Werving
- Collaborative Neuroscience Research, LLC
-
Contact:
- CNS Outreach Department
- Telefoonnummer: 844-424-9494
- E-mail: cns.outreach@cenexel.com
-
La Jolla, California, Verenigde Staten, 92037
- Werving
- Kadima Neuropsychiatry Institute
-
Contact:
- Angelica Lu
- Telefoonnummer: 858-775-2053
- E-mail: angelical@kadimanp.com
-
San Francisco, California, Verenigde Staten, 94114
- Werving
- Open Mind Therapeutics
-
Contact:
- Victoria Vega
- Telefoonnummer: 415-906-7399
- E-mail: victoria@openmindcollective.org
-
Santa Monica, California, Verenigde Staten, 90404
- Werving
- TRIP Clinic at Psychedelic Science Institute
-
Contact:
- Ashley Ramos
- E-mail: trialadmin@psychedlicsci.com
-
-
Florida
-
Lauderhill, Florida, Verenigde Staten, 33319
- Werving
- Innovative Clinical Research, Inc.
-
Contact:
- Melissa Rodco
- Telefoonnummer: 305-722-8444
- E-mail: mrodco@segaltrials.com
-
Tampa, Florida, Verenigde Staten, 33613
- Werving
- University of South Florida
-
Contact:
- Genesis Estramera
- Telefoonnummer: 813-974-1404
- E-mail: gestramera@usf.edu
-
-
Georgia
-
Atlanta, Georgia, Verenigde Staten, 30331
- Werving
- Atlanta Center for Medical Research
-
Contact:
- Amber Tannahill
- Telefoonnummer: 404-881-5800
- E-mail: a.tannahill@cenexel.com
-
Decatur, Georgia, Verenigde Staten, 30030
- Werving
- CenExel iResearch, LLC
-
Contact:
- Michael Mahaffrey
- E-mail: m.mahaffrey@cenexel.com
-
Norcross, Georgia, Verenigde Staten, 30092
- Werving
- Evergreen Clinical Trials
-
Contact:
- Stephen Wheeler
- Telefoonnummer: 943-230-1385
- E-mail: stephen@evergreenstrials.com
-
Savannah, Georgia, Verenigde Staten, 31405
- Werving
- CenExel iResearch, LLC
-
Contact:
- Michelle Lagares
- Telefoonnummer: 912-744-0800
- E-mail: M.Lagares@CenExel.com
-
-
Illinois
-
Chicago, Illinois, Verenigde Staten, 60640
- Werving
- Uptown Research Institute
-
Contact:
- Deborah Jones-Miller
- Telefoonnummer: 117 773-989-8313
- E-mail: Djones-miller@uptownresearch.com
-
-
Michigan
-
Novi, Michigan, Verenigde Staten, 48377
- Werving
- Henry Ford Medical Center - Columbus
-
Contact:
- Madeline Bross
- Telefoonnummer: 248-344-7366
- E-mail: mbross1@hfhs.org
-
-
Missouri
-
Saint Charles, Missouri, Verenigde Staten, 63304
- Werving
- Midwest Research Group
-
Contact:
- Lindsay vanWinkle
- Telefoonnummer: 3 636-946-8032
- E-mail: lvanwinkle@midwestresearchgroup.com
-
-
New Mexico
-
Albuquerque, New Mexico, Verenigde Staten, 14624
- Werving
- UNM Research Program Psychedelic Therapies
-
Contact:
- Hector Garcia
- Telefoonnummer: 505-675-0582
- E-mail: hecgarcia@salud.unm.edu
-
-
New York
-
New York, New York, Verenigde Staten, 10016
- Werving
- NYU-H+C Clinical and Translational Science Institute
-
Contact:
- Jillian Kelly
- Telefoonnummer: 212-404-7764
- E-mail: Jillian.kelly@nyulangone.org
-
-
North Carolina
-
Chapel Hill, North Carolina, Verenigde Staten, 27514
- Werving
- University of North Carolina at Chapel Hill
-
Contact:
- Julia Hoffman
- E-mail: julia_hoffmann1@med.unc.edu
-
-
Ohio
-
North Canton, Ohio, Verenigde Staten, 44720
- Werving
- Neuro-Behavioral Clinical Research, Inc.
-
Contact:
- Crystal Blackford
- Telefoonnummer: 330-493-1118
- E-mail: cblackford@nb-cr.com
-
-
Oregon
-
Portland, Oregon, Verenigde Staten, 97210
- Werving
- Summit Headlands LLC
-
Contact:
- Tyler Leecing
- E-mail: tyler.leecing@summitnetwork.com
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, Verenigde Staten, 19104
- Werving
- University of Pennsylvania
-
Contact:
- Erin Blase
- Telefoonnummer: 215-746-6419
- E-mail: erin.blase@pennmedicine.upenn.edu
-
West Chester, Pennsylvania, Verenigde Staten, 19380
- Ingetrokken
- Suburban Research Associates
-
-
Texas
-
Austin, Texas, Verenigde Staten, 78737
- Werving
- Austin Clinical Trial Partners
-
Contact:
- Kara Chilek
- Telefoonnummer: 512-521-0595
- E-mail: studyinfo@austinCTP.com
-
Austin, Texas, Verenigde Staten, 78759
- Werving
- BioBehavioral Research Austion
-
Contact:
- Tracie Wesson
- Telefoonnummer: 402-934-0044
- E-mail: tracie.wesson@qcrnetwork.com
-
Plano, Texas, Verenigde Staten, 75093
- Werving
- Aim Trials, LLC
-
Contact:
- Sonia Prashar
- Telefoonnummer: 214-856-2778
- E-mail: sonia.prashar@aimtrials.com
-
-
Utah
-
Draper, Utah, Verenigde Staten, 84020
- Werving
- Cedar Clinical Research
-
Contact:
- Jane Bjorklund
- Telefoonnummer: 801-369-4219
- E-mail: jane.bjorklund@numinusnetwork.com
-
Orem, Utah, Verenigde Staten, 84058
- Werving
- Inner Space State Street
-
Contact:
- Janet Jimenez
- Telefoonnummer: 801-871-5516
- E-mail: apply@innerspaceresearch.com
-
-
Deelname Criteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
Accepteert gezonde vrijwilligers
Geslachten die in aanmerking komen voor studie
Beschrijving
Inclusion Criteria:
- Has Generalized Anxiety Disorder as defined by DSM-5-TR
- If female is not pregnant or planning to become pregnant. If male is not planning to make a partner pregnant.
- Is willing and able to comply with the conditions and requirements of the study
Exclusion Criteria:
- Has a significant risk of suicide
- Has an active or medical history of bipolar disorder, schizophrenia, schizoaffective disorder, psychotic disorder and/or borderline personality disorder, or first-degree family history of psychosis or bipolar disorder
- Has other concurrent psychiatric disorders that is the primary disorder.
- Has other medically significant conditions rendering unsuitability for the study
- Has used or will need to use prohibited medications or therapies
- Has a known sensitivity or intolerance to study intervention or potential rescue medications
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Behandeling
- Toewijzing: Gerandomiseerd
- Interventioneel model: Parallelle opdracht
- Masker: Verdrievoudigen
Wapens en interventies
Deelnemersgroep / Arm |
Interventie / Behandeling |
|---|---|
|
Placebo-vergelijker: Placebo
A single subcutaneous injection of 0.9% sodium chloride for injection per dosing session |
Single-dose (Part A) or Repeat-dose (Part B), subcutaneous injection(s) of 0.9% sodium chloride for injection |
|
Experimenteel: 30 mg RE104
A single subcutaneous injection of 30 mg RE104 for Injection per dosing session |
Single dose (Part A) or Repeat-dose (Part B), subcutaneous injection(s) of RE104 for Injection |
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
RE104 when administered as a single 30 mg dose or as two 30 mg doses 3 weeks apart versus placebo change from Baseline at Week 4 in Hamilton Anxiety Rating Scale (HAM-A) total score
Tijdsspanne: Week 4
|
The Hamilton Rating Scale for Anxiety (HAM-A) is a 14-item scale that is used to rate the severity of symptoms of anxiety. The total score ranges from 0-56 with higher scores representing greater severity of anxiety. |
Week 4
|
Secundaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
RE104 versus placebo changes in total score from baseline in Hamilton Anxiety Rating Scale (HAM-A)
Tijdsspanne: Weeks 1, 2, 8 and 12
|
The Hamilton Rating Scale for Anxiety (HAM-A) is a 14-item scale that is used to rate the severity of symptoms of anxiety. The total score ranges from 0-56 with higher scores representing greater severity of anxiety. |
Weeks 1, 2, 8 and 12
|
|
RE104 versus placebo percentage of participants with HAM-A response (≥50% reduction in score from Baseline)
Tijdsspanne: Weeks 1, 2, 4, 8 and 12
|
The Hamilton Rating Scale for Anxiety (HAM-A) is a 14-item scale that is used to rate the severity of symptoms of anxiety. The total score ranges from 0-56 with higher scores representing greater severity of anxiety. |
Weeks 1, 2, 4, 8 and 12
|
|
RE104 versus placebo percentage of participants with HAM-A remission (total score ≤7)
Tijdsspanne: Day 1 and Weeks 1, 2, 4, 8 and 12
|
The Hamilton Rating Scale for Anxiety (HAM-A) is a 14-item scale that is used to rate the severity of symptoms of anxiety. The total score ranges from 0-56 with higher scores representing greater severity of anxiety. |
Day 1 and Weeks 1, 2, 4, 8 and 12
|
|
RE104 versus placebo change from Baseline at Weeks 1, 2, 4, 8, and 12 in Hospital Anxiety and Depression Scale (HADS) depression subscore
Tijdsspanne: Weeks 1, 2, 4, 8 and 12
|
The Hospital Anxiety and Depression Scale (HADS) is a self-reported scale measure the severity of depression and anxiety in patients with comorbid medical conditions. The scale consists of 14 items (7 for anxiety and 7 for depression), with a score ranging between 0 and 21 for the anxiety and depression subscales. |
Weeks 1, 2, 4, 8 and 12
|
|
RE104 versus placebo incidence of treatment-emergent adverse events (TEAEs) by frequency, severity and seriousness.
Tijdsspanne: From dosing through study completion (post-dose follow-up is for 12 weeks)
|
A treatment-emergent adverse event (TEAE) is defined as any unfavorable and unintended sign, symptom or disease temporally associated with the use of a study drug. |
From dosing through study completion (post-dose follow-up is for 12 weeks)
|
|
RE104 versus placebo change from Baseline in Montgomery-Åsberg Depression Rating Scale (MADRS) (Part B only)
Tijdsspanne: Weeks 1, 2, 4, 8, and 12
|
The Montgomery-Åsberg Depression Rating Scale (MADRS) is a 10-item clinician rated scale measuring depression severity. The total score ranges from 0-60 with higher scores representing greater severity of depression. |
Weeks 1, 2, 4, 8, and 12
|
Medewerkers en onderzoekers
Sponsor
Onderzoekers
- Studie directeur: Mark Pollack, M.D., Reunion Neuroscience Inc
Studie record data
Bestudeer belangrijke data
Studie start (Werkelijk)
Primaire voltooiing (Geschat)
Studie voltooiing (Geschat)
Studieregistratiedata
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Werkelijk)
Updates van studierecords
Laatste update geplaatst (Werkelijk)
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Trefwoorden
Aanvullende relevante MeSH-voorwaarden
Andere studie-ID-nummers
- RE104-203-GAD
Plan Individuele Deelnemersgegevens (IPD)
Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?
Beschrijving IPD-plan
Data sharing will be consistent with the results submission policy of ClinicalTrials.gov.
Informatie over medicijnen en apparaten, studiedocumenten
Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel
Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .